Sarah Cannon Research Institute Grows Network with Addition of Mary Crowley Cancer Research

January 6, 2025

Early-phase drug development center joins leading cancer research organization to expand clinical trial access for patients throughout North Texas

DALLAS, Texas & NASHVILLE, Tenn. (January 6, 2025) – Today, Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, proudly announced the acquisition of Mary Crowley Cancer Research, a distinguished center in Dallas that specializes in early-phase clinical research. This strategic addition furthers SCRI's commitment to expand access to cutting-edge therapies to patients within their own communities.

For more than 25 years, Mary Crowley Cancer Research has been at the forefront of early-phase research, conducting more than 800 clinical trials in collaboration with Texas Oncology physicians who serve as principal and sub-investigators. This legacy of innovation and excellence will continue under the new banner, SCRI at Mary Crowley, offering an expanded clinical trial menu, strengthened research capabilities and access to Genospace, SCRI’s personalized medicine platform, which transforms patient data into actionable insights for treatment.

"We are thrilled to welcome the talented research teams at Mary Crowley into the SCRI network," said Dee Anna Smith, Chief Executive Officer of SCRI. "We look forward to deepening our longstanding collaboration with the esteemed Texas Oncology physicians by enhancing research operations and support at this pivotal North Texas research center. Together, we are uniquely positioned to make a transformative impact on the lives of people facing cancer, providing them with innovative treatment options close to home."

SCRI is a global leader in oncology research, including early phase research. It has conducted more than 800 first-in-human clinical trials since its inception and its contributions to research have helped to advance most new cancer therapies approved by the FDA today. With the addition of Mary Crowley Cancer Research, SCRI now operates eight early-phase drug development units across the United States and actively enrolls patients into clinical trials at more than 250 locations in 24 states.

About SCRI

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 800 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Visit scri.com to learn more.